Comparison of leucovorin protection from variety of antifolates in human lymphoid cell lines.

abstract：PURPOSE:Epigenetic silencing of tumor suppressor genes (TSGs) by aberrant DNA methylation and chromatin deacetylation provides interesting targets for chemotherapeutic intervention by inhibitors of these events. 5-Aza-2'-deoxycytidine (decitabine, 5AZA-CdR) is a potent demethylating agent, which can reactivate TSGs sil...

journal_title：Cancer chemotherapy and pharmacology

authors： Hurtubise A,Momparler RL

更新日期：2006-11-01 00:00:00

abstract：PURPOSE:Our study was designed to evaluate the efficacy and safety of everolimus in patients with pre-treated metastatic gastric and esophagus cancers in a US-based population focusing on biomarker correlation. METHODS:Patients with advanced upper GI adenocarcinomas who progressed after 1-2 prior regimens received eve...

journal_title：Cancer chemotherapy and pharmacology

authors： Wainberg ZA,Soares HP,Patel R,DiCarlo B,Park DJ,Liem A,Wang HJ,Yonemoto L,Martinez D,Laux I,Brennan M,Hecht JR

更新日期：2015-07-01 00:00:00

abstract：:A simple fluorescent microscopic method demonstrated that adriamycin was distributed in two cellular compartments of living rat colon cancer cells. Adriamycin accumulated slowly in cytoplasmic granules, probably lysosomes, where it persisted long after the drug was removed from the medium. On the other hand, adriamyci...

journal_title：Cancer chemotherapy and pharmacology

authors： Chauffert B,Martin F,Caignard A,Jeannin JF,Leclerc A

更新日期：1984-01-01 00:00:00

abstract：PURPOSE:Although intra-arterial chemotherapy (IAC) is commonly used for treating intraocular retinoblastoma, it is not a systemic therapy. We aimed to investigate whether the addition of intravenous chemotherapy (IVC) before IAC administration had any effects (whether beneficial or adverse) on patient outcomes. METHOD...

journal_title：Cancer chemotherapy and pharmacology

authors： Chen Q,Zhang B,Dong Y,Mo X,Zhang L,Xia J,Zhang J,Zhang S

更新日期：2020-04-01 00:00:00

abstract：:The interactions of cisplatin, 5-fluorouracil, doxorubicin, mitomycin, carmustine (BCNU), cyclophosphamide, methotrexate and thio-TEPA were assessed at three neurotransmitter receptor binding sites. Each drug was inactive at concentrations as high as 10(-4) M in displacing the specific binding of 3H-spiperone to dopam...

journal_title：Cancer chemotherapy and pharmacology

authors： Peroutka SJ

更新日期：1987-01-01 00:00:00

abstract：PURPOSE:Radiotherapy (RTx) has been considered as the treatment for locally advanced squamous cell carcinoma of the head and neck (SCCHN). However, with only conventional fractionation (Cfx), response rates are relatively low. In this study, we report the results of hyperfractionation (Hfx) RTx with concurrent docetaxe...

journal_title：Cancer chemotherapy and pharmacology

authors： Katori H,Tsukuda M,Watai K

更新日期：2007-08-01 00:00:00

abstract：PURPOSE:Irinotecan-induced gut toxicity is mediated in part by Toll-Like receptor 4 (TLR4) signalling. The primary purpose of this preclinical study was to determine whether blocking TLR4 signalling by administering (-)-naloxone, a TLR4 antagonist, would improve irinotecan-induced gut toxicity. Our secondary aim was to...

journal_title：Cancer chemotherapy and pharmacology

authors： Coller JK,Bowen JM,Ball IA,Wardill HR,van Sebille YZ,Stansborough RL,Lightwala Z,Wignall A,Shirren J,Secombe K,Gibson RJ

更新日期：2017-02-01 00:00:00

abstract：PURPOSE:To assess the activity and safety of combined folinic acid (FA), 5-fluorouracil (5-FU) and mitomycin C (MMC) in metastatic breast cancer patients previously treated with at least two chemotherapy regimens. PATIENTS AND METHODS:A total of 104 consecutive patients were enrolled for treatment with FA 100 mg/m(2) ...

journal_title：Cancer chemotherapy and pharmacology

authors： Francini G,Petrioli R,Messinese S,Pozzessere D,Marsili S,Correale P,Sabatino M,Fiaschi AI

更新日期：2002-10-01 00:00:00

abstract：:Isothiocyanate sulforaphane (SFN) is a potent cancer chemopreventive agent. We investigated the mechanisms underlying the anti-proliferative effects of SFN in the human colon carcinoma cell line, HT-29. We demonstrate that SFN inhibits the growth of HT-29 cells in a dose- and time-dependent manner. Treatment of serum-...

journal_title：Cancer chemotherapy and pharmacology

authors： Shen G,Xu C,Chen C,Hebbar V,Kong AN

更新日期：2006-02-01 00:00:00

abstract：PURPOSE:The combination of docetaxel, cisplatin and 5-fluorouracil (DCF) is a newly developed chemotherapy regimen for esophageal cancer. Severe neutropenia is dose-limiting toxicity of docetaxel and it is well known to be frequently occurred during DCF chemotherapy. This study aimed to investigate the relationship bet...

journal_title：Cancer chemotherapy and pharmacology

authors： Nomura H,Tsuji D,Demachi K,Mochizuki N,Matsuzawa H,Yano T,Daiko H,Fujii S,Kojima T,Itoh K,Kawasaki T

更新日期：2020-08-01 00:00:00

abstract：:To test the feasibility of a regimen of high-dose cisplatin, ifosfamide, and etoposide (VP-16; VIPP regimen), we registered 15 patients with advanced non-small-cell lung cancer in a phase I trial of the Northern California Oncology Group. One cycle of treatment consisted of high-dose cisplatin given at 100 mg/m2 i.v. ...

journal_title：Cancer chemotherapy and pharmacology

authors： Perez EA,Sowray PC,Gardner SL,Gandara DR

更新日期：1994-01-01 00:00:00

abstract：PURPOSE:Standardized enumeration of CEC counts is required to minimize variability and allow cross-studies comparisons. The purpose of this paper is to identify CEC threshold proposal, by CellSearch system, for determining response to bevacizumab-based chemotherapy in metastatic colorectal cancer. METHODS:From July 20...

journal_title：Cancer chemotherapy and pharmacology

authors： Matsusaka S,Suenaga M,Mishima Y,Takagi K,Terui Y,Mizunuma N,Hatake K

更新日期：2011-09-01 00:00:00

abstract：:The effects of heat on intracellular accumulation of anthracyclines were investigated by laser flow cytometry analysis. Sarcoma-180 cells were exposed to Adriamycin (ADM), epirubicin (EPIR), daunomycin (DM), THP-Adriamycin (THP), ME-2303 (ME) and KRN-8602 (KRN) at 37 degrees C and at higher temperatures. There was a d...

journal_title：Cancer chemotherapy and pharmacology

authors： Sakaguchi Y,Maehara Y,Inutsuka S,Takahashi I,Yoshida M,Emi Y,Baba H,Sugimachi K

更新日期：1994-01-01 00:00:00

abstract：BACKGROUND:We investigated the efficacy and safety of 60, 120, or 240 mg of Z-360, which is a highly potent cholecystokinin2-receptor-selective antagonist, combined with gemcitabine in patients with metastatic pancreatic cancer. METHODS:Patients were randomly assigned in a 1:1:1:1 ratio to one of four treatment groups...

journal_title：Cancer chemotherapy and pharmacology

authors： Ueno M,Li CP,Ikeda M,Ishii H,Mizuno N,Yamaguchi T,Ioka T,Oh DY,Ichikawa W,Okusaka T,Matsuyama Y,Arai D,Chen LT,Park YS,Furuse J

更新日期：2017-08-01 00:00:00

abstract：:Paclitaxel is used as a single agent, and in combination with other drugs, as a standard of care in the treatment of squamous cell carcinoma of the head and neck (SCCHN). However, the use of paclitaxel for therapy of SCCHN may be accompanied by serious side effects. Paclitaxel is a known cytotoxic inhibitor of cell pr...

journal_title：Cancer chemotherapy and pharmacology

authors： Jaglowski JR,Zagon IS,Stack BC Jr,Verderame MF,Leure-duPree AE,Manning JD,McLaughlin PJ

更新日期：2005-07-01 00:00:00

abstract：:Mercaptopurine (6MP) has been the standard drug for maintenance therapy of acute lymphoblastic leukemia. In a multicenter study we investigated whether thioguanine (6TG), which is converted more directly to the cytotoxic thioguanine nucleotides (TGN), offers a therapeutic advantage over 6MP. In this study (COALL-92), ...

journal_title：Cancer chemotherapy and pharmacology

authors： Erb N,Harms DO,Janka-Schaub G

更新日期：1998-01-01 00:00:00

abstract：PURPOSE:To evaluate the feasibility, toxicity and efficacy of the combination of docetaxel and mitomycin C as second-line chemotherapy in patients with advanced non-small cell lung cancer (NSCLC). PATIENTS AND METHODS:Thirty-eight patients with histologically confirmed, locally advanced or metastatic NSCLC were includ...

journal_title：Cancer chemotherapy and pharmacology

authors： Feliu J,Martín G,Castro J,Sundlov A,Rodriguez-Jaráiz A,Casado E,Lomas M,Madroñal C,Galán A,Belda C,Gonzalez-Barón M

更新日期：2006-10-01 00:00:00

abstract：PURPOSE:This phase II study was performed to evaluate the efficacy and safety of cisplatin/pemetrexed combined with 15 mg/kg of bevacizumab followed by pemetrexed/bevacizumab maintenance therapy as first-line chemotherapy in advanced non-squamous non-small cell lung cancer (NSCLC) limited to epidermal growth factor rec...

journal_title：Cancer chemotherapy and pharmacology

authors： Fukushima T,Wakatsuki Y,Kobayashi T,Sonehara K,Tateishi K,Yamamoto M,Masubuchi T,Yoshiike F,Hirai K,Hachiya T,Koizumi T

更新日期：2018-06-01 00:00:00

abstract：PURPOSE:PF-00337210 is an oral, highly selective vascular endothelial growth factor receptor (VEGFR) inhibitor. We evaluated a composite of biomarkers in real time to identify the recommended phase 2 dose (RP2D) and preliminary anticancer activity of PF-00337210. PATIENTS AND METHODS:Patients (Pts) with advanced cance...

journal_title：Cancer chemotherapy and pharmacology

authors： Bruce JY,LoRusso PM,Goncalves PH,Heath EI,Sadowski E,Shalinsky DR,Zhang Y,Traynor AM,Breazna A,Ricart AD,Tortorici M,Liu G

更新日期：2016-03-01 00:00:00

abstract：PURPOSE:The combination of an mTOR inhibitor with 5-fluorouracil-based anticancer therapy is attractive because of preclinical evidence of synergy between these drugs. According to our phase I study, the combination of capecitabine and everolimus is safe and feasible, with potential activity in pancreatic cancer patien...

journal_title：Cancer chemotherapy and pharmacology

authors： Kordes S,Klümpen HJ,Weterman MJ,Schellens JH,Richel DJ,Wilmink JW

更新日期：2015-06-01 00:00:00

abstract：PURPOSE:P-glycoprotein is a 170-kDa plasma membrane multidrug transporter that actively exports cytotoxic substances from cells. Overexpression of P-glycoprotein by tumor cells is associated with a multidrug-resistant phenotype. Immunosuppressive agents such as cyclosporins and macrolides, have been shown to attenuate ...

journal_title：Cancer chemotherapy and pharmacology

authors： Mealey KL,Barhoumi R,Burghardt RC,McIntyre BS,Sylvester PW,Hosick HL,Kochevar DT

更新日期：1999-01-01 00:00:00

abstract：:The pharmacokinetics of doxorubicin (DOX) and doxorubicinol (DOXol) was studied in six patients with various advanced neoplastic diseases who received 28-72 mg/m2 DOX (nine courses). Plasma and parotid saliva were collected over a 48-h period, and DOX and DOXol were quantified by high-performance liquid chromatography...

journal_title：Cancer chemotherapy and pharmacology

authors： Bressolle F,Jacquet JM,Galtier M,Jourdan J,Donadio D,Rossi JF

更新日期：1992-01-01 00:00:00

abstract：PURPOSE:Malignant gliomas display aggressive local behavior and are not cured by existing therapy. Etoposide, a topoisomerase-II-inhibitor agent, is one of the most active and useful antineoplastic agents. However, etoposide is not usually used on these tumors. We undertook an in vitro study to prove that etoposide is ...

journal_title：Cancer chemotherapy and pharmacology

authors： Beauchesne P,Bertrand S,N'guyen MJ,Christianson T,Dore JF,Mornex F,Bonner JA

更新日期：1998-01-01 00:00:00

abstract：:The pharmacokinetics of pentamethylmelamine (PMM) have been investigated in mouse (Balb C-, CBA/LAC, nude), rat (Wistar), and man. In all three species, PMM was extensively demethylated to N2,N2,N4,N6-tetramethylmelamine and N2,N4,N6-trimethylmelamine, although marked species differences in the rate of metabolism were...

journal_title：Cancer chemotherapy and pharmacology

authors： Rutty CJ,Newell DR,Muindi JR,Harrap KR

更新日期：1982-01-01 00:00:00

abstract：PURPOSE:We conducted a phase II trial to evaluate the efficacy and safety of induction chemotherapy of pemetrexed plus split-dose cisplatin followed by pemetrexed maintenance for advanced non-squamous non-small-cell lung cancer (NSCLC). METHODS:Patients with advanced or recurrent untreated non-squamous NSCLC received ...

journal_title：Cancer chemotherapy and pharmacology

authors： Koba T,Minami S,Nishijima-Futami Y,Masuhiro K,Kimura H,Futami S,Yaga M,Mori M,Kagawa H,Uenami T,Kohmo S,Otsuka T,Yamamoto S,Komuta K,Kijima T

更新日期：2018-07-01 00:00:00

abstract：:Melphalan (L-PAM) pharmacokinetics were investigated in nine ovarian cancer patients before and after cisplatin (DDP) treatment. When L-PAM was given 24 h before DDP, the elimination half-life (t 1/2 beta), plasma clearance (Clp), and volume of distribution (Vd beta) of L-PAM were, respectively: 46.4 +/- 6.7 min, 20.5...

journal_title：Cancer chemotherapy and pharmacology

authors： Zucchetti M,D'Incalci M,Willems Y,Cavalli F,Sessa C

更新日期：1988-01-01 00:00:00

abstract：PURPOSE:This study was performed to determine the maximum tolerated dose (MTD) and toxicity of vinorelbine when used in combination with doxorubicin and methotrexate with leucovorin rescue in women with metastatic breast cancer. METHODS:Enrolled in the study were 23 women with metastatic breast cancer who had not rece...

journal_title：Cancer chemotherapy and pharmacology

authors： Subramanyan S,Abeloff MD,Bond SE,Davidson NE,Fetting JH,Gordon GB,Kennedy MJ

更新日期：1999-01-01 00:00:00

abstract：BACKGROUND:Aprepitant is a selective neurokinin-1 receptor antagonist that is effective for the prevention of nausea and vomiting caused by highly emetogenic chemotherapy. In vitro, aprepitant is a moderate inhibitor of the CYP3A4 enzyme, which is involved in the clearance of several chemotherapeutic agents. In this st...

journal_title：Cancer chemotherapy and pharmacology

authors： Nygren P,Hande K,Petty KJ,Fedgchin M,van Dyck K,Majumdar A,Panebianco D,de Smet M,Ahmed T,Murphy MG,Gottesdiener KM,Cocquyt V,van Belle S

更新日期：2005-06-01 00:00:00

abstract：OBJECTIVE:Poly(ADP-ribosyl) polymerases (PARPs) are nuclear enzymes with roles in DNA damage recognition and repair. PARP1 inhibition enhances the effects of DNA-damaging agents like doxorubicin. We sought to determine the recommended phase two dose (RP2D) of veliparib with pegylated liposomal doxorubicin (PLD) in brea...

journal_title：Cancer chemotherapy and pharmacology

authors： Pothuri B,Brodsky AL,Sparano JA,Blank SV,Kim M,Hershman DL,Tiersten A,Kiesel BF,Beumer JH,Liebes L,Muggia F

更新日期：2020-04-01 00:00:00

abstract：PURPOSE:The objectives of this phase I dose-finding study of erlotinib were to investigate the toxicity profile, to confirm the acceptable toxicity of doses up to 150 mg/day, and to assess the pharmacokinetic (PK) profile and antitumor activity in Japanese patients with solid tumors. PATIENTS AND METHODS:Patients with...

journal_title：Cancer chemotherapy and pharmacology

authors： Yamamoto N,Horiike A,Fujisaka Y,Murakami H,Shimoyama T,Yamada Y,Tamura T

更新日期：2008-03-01 00:00:00